Enhancement of cerebral diseases: How much contrast agent is enough?: Comparison of 0.1, 0.2, and 0.3 mmol/kg gadoteridol at 0.2 T with 0.1 mmol/kg gadoteridol at 1.5 T

Investigative Radiology

Volumn 36, Issue 5, 2001, Pages 266-275

  Brekenfeld, Caspar ^a,f   Foert, Ellen ^b   Hundt, Walter ^c   Kenn, Werner ^d   Lodeann, Klaus Peter ^e   Gehl, Hans Björn ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^e ALTANA PHARMA AG   (Germany)

^f UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Brain lesions; Contrast media; Low field MRI; MRI

Indexed keywords

GADOTERIDOL;

ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; BRAIN DISEASE; BRAIN SCINTISCANNING; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DOSE CALCULATION; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0035024018     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-200105000-00004     Document Type: Article

References (21)

1. Russell EJ, Geremia GK, Johnson CE, et al. Multiple cerebral metastases: Detectability with gadopentetate-dimeglumine-enhanced MR imaging. Radiology 1987;165:609-619.
2. Felix R, Schörner W, Laniado M, et al. Brain tumors: MR imaging with gadolinium-DTPA. Radiology 1985;156:681-688.
3. Niendorf HP, Laniado M, Semmler W, et al. Dose administration of gadolinium-DTPA in MR imaging of intracranial tumors. AJNR 1987;8:803-815.
4. Russell EJ, Schaible TF, Dillon W, et al. Multicentre double-blind placebo-controlled study of gadopentetate dimeglumine as an MR contrast agent: Evaluation in patients with cerebral lesions. AJNR 1989;10:53-63.
5. Schubeus P, Schörner J, Haustein J, et al. Dosisoptimierung von Gadolinium-DTPA: Eine interindividuelle Studie an Patienten mit intrakraniellen Tumoren. Fortschr Röntgenstr 1990;153:29-35.
6. Haustein J, Laniado M, Niendorf HP, et al. Administration of gadopentetate dimeglumine in MR imaging of intracranial tumors: Dosage and field strength. AJNR 1992;13:1199-1206.
7. Runge VM, Gelblum DY, Pacetti ML, et al. GD-HP-DO3A in clinical MR imaging of the brain. Radiology 1990;177:393-400.
8. Yuh WTC, Fisher DJ, Engelken JD, et al. MR evaluation of CNS tumors: Dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology 1991;180:485-491.
9. Crooks LE, Arakawa M, Hoenninger J, et al. Magnetic resonance imaging: Effects of magnetic field strength. Radiology 1984;151: 127-133.
10. Rinck PA, Fischer HW, Elst LV, et al. Field-cycling relaxometry: Medical applications. Radiology 1988;168:843-849.
11. Lindsey RO, Yetkin Z, Prost R, et al. Effect of dose and field strength on enhancement with paramagnetic contrast media. AJNR 1994; 15:1849-1852.
12. Chang KH, Ra DG, Han MH, et al. Contrast enhancement of brain tumors at different MR field strengths: Comparison of 0.5 T and 2.0 T. AJNR 1994;15:1413-1419.
13. Elster AD. How much contrast is enough? Dependence of enhancement on field strength and MR pulse sequence Eur Radiol 1997; 7(suppl 5):276-280.
14. Yuh WTC, Tali ET, Nguyen HD, et al. The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis. AJNR 1995;16:373-380.
15. Lemke AJ, Sander B, Balzer T, et al. Sicherheit und Nutzen von Gadubutrol bei Patienten mit zerebralen Tumoren (Phase-III-Studie). Fortschr Rontgenstr 1997;167:591-598.
16. Yuh WTC, Engelken JD, Muhonen MG et al. Experience with high-dose gadolinium MR imaging in the evaluation of brain metastases. AJNR 1992;13:335-345.
17. Healy ME, Hesselink JR, Press GA, et al. Increased detection of intracranial metastases with intravenous gadopentetate-dimeglumine. Radiology 1987;165:619-624.
18. Rinck PA, Muller RN. Field strength and dose dependence of contrast enhancement by gadolinium-based MR contrast agents. Eur Radiol 1999;9:998-1004.
19. Sze G, Milano E, Johnson C, et al. Detection of brain metastases: Comparison of contrast-enhanced MR with unenhanced MR and enhanced CT. AJNR 1990;11:785-791.
20. Davis PC, Hudgins PA, Peterman SB, et al. Diagnosis of cerebral metastases: Double-dose delayed CT vs contrast-enhanced MR imaging. AJR 1991;156:1039-1046.
21. Kormano M, Niemi P, Paajanen H, et al. The utility of contrast media in MRI at 0.02 T. Invest Radiol 1988;23:289-291.